

## **DSM Pharmaceutical Products**

45 Waterview Blvd  
Parsippany, NJ 07054-1298

### **DSM Pharmaceutical Products Announces Management Appointments to Capitalize on Significant Pharmaceutical Outsourcing Growth Opportunities**

(Parsippany – September 21, 2007)

DSM Pharmaceutical Products, a leading provider of custom contract manufacturing services, announced today the following management appointments.

**Mr. Leendert Staal**, currently Business Group Director DSM Pharmaceutical Products, will be appointed President of DSM Nutritional Products, reporting to Stephan Tanda, member of the Managing Board of DSM.

**Mr. Bob Hartmayer** will succeed Mr. Staal as Business Group Director, President & CEO of DSM Pharmaceutical Products, reporting to Jan Zuidam, member of the Managing Board of DSM. Mr. Hartmayer currently holds the position of Business Group Director DSM Elastomers.

As the pharmaceutical business group is now moving into a significant period of growth, involving both autonomous and non-autonomous opportunities, the following management appointments will take effect on October 1, 2007;

**Mr. Luca Mantovani**, currently Vice President Citric Acid, DSM Nutritional Products, will be appointed Business Unit Director, President DSM Pharma Chemicals reporting to Mr. Hartmayer.

**Mr. Terry Novak**, currently Chief Marketing Officer DSM Pharmaceuticals & Biologics, will be appointed Business Unit Director, President DSM Pharmaceuticals Inc. reporting to Mr. Hartmayer.

**Ms. Karen King**, currently Sr. VP Strategic Business Development, will be appointed Business Unit Director, President DSM Biologics reporting to Mr. Hartmayer.

**Mr. Hans Engels**, currently Chief Operating Officer DSM Pharmaceuticals & Biologics will be appointed Chief Operating Officer, DSM Pharmaceutical Products Business Group reporting to Mr. Hartmayer.

**Mr. Stephen Lijoi**, currently VP Operations Greenville, will be appointed Vice President and Site Director for DSM Pharmaceuticals Greenville, NC site reporting to Mr. Novak.

#### **About DSM Pharmaceutical Products**

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal

antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.

From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers' unique manufacturing needs.

## **About DSM**

DSM is active worldwide in [nutritional and pharma ingredients, performance materials and industrial chemicals](#). The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named [Vision 2010 – Building on Strengths](#), focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with [locations](#) in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at [www.dsm.com](http://www.dsm.com).

## **Forward-looking statements**

*This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.*

## **For more information:**

### **DSM Pharmaceutical Products**

Terry Novak  
Chief Marketing Officer  
DSM Pharmaceuticals Inc. and DSM Biologics  
973-257-8471  
[Terry.Novak@dsm.com](mailto:Terry.Novak@dsm.com)